Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2008

01-05-2008 | Original article

Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis

Authors: Hiroshi Ohira, Ichizo Tsujino, Shinji Ishimaru, Noriko Oyama, Toshiki Takei, Eriko Tsukamoto, Masatake Miura, Shinji Sakaue, Nagara Tamaki, Masaharu Nishimura

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2008

Login to get access

Abstract

Purpose

Despite accumulating reports on the clinical value of 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET) and magnetic resonance imaging (MRI) in the assessment of cardiac sarcoidosis, no studies have systematically compared the images of these modalities.

Methods

Twenty-one consecutive patients with suspected cardiac sarcoidosis underwent cardiac examinations that included 18F-FDG PET and MRI. The association of 18F-FDG PET and MRI findings with blood sampling data such as serum angiotensin converting enzyme levels was also evaluated.

Results

Eight of 21 patients were diagnosed as having cardiac sarcoidosis according to the Japanese Ministry of Health and Welfare Guidelines for Diagnosing Cardiac Sarcoidosis. Sensitivity and specificity for diagnosing cardiac sarcoidosis were 87.5 and 38.5%, respectively, for 18F-FDG PET, and 75 and 76.9%, respectively, for MRI. When the 18F-FDG PET and MRI images were compared, 16 of 21 patients showed positive findings in one (n = 8) or both (n = 8) of the two modalities. In eight patients with positive findings on both images, the distribution of the findings differed among all eight cases. The presence of positive findings on 18F-FDG PET was associated with elevated serum angiotensin-converting enzyme levels; this association was not demonstrated on MRI.

Conclusions

Both 18F-FDG PET and MRI provided high sensitivity for diagnosing cardiac sarcoidosis in patients with suspected cardiac involvement, but the specificity of 18F-FDG PET was not as high as previously reported. The different distributions of the findings in the two modalities suggest the potential of 18F-FDG PET and MRI in detecting different pathological processes in the heart.
Literature
1.
Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.CrossRefPubMed
2.
Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 1976;278:455-69.CrossRefPubMed
3.
4.
5.
Lorell B, Alderman EL, Mason JW. Cardiac sarcoidosis. Diagnosis with endomyocardial biopsy and treatment with corticosteroid. Am J Cardiol 1978;42:143-6.CrossRefPubMed
6.
Ishikawa T, Kondoh H, Nakagawa S, Koiwaya Y, Tanaka K. Steroid therapy in cardiac sarcoidosis. Increased left ventricular contractility concomitant with electrocardiographic improvement after prednisolone. Chest 1984;85:445-7.CrossRefPubMed
7.
Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med 1977;63:86-108.CrossRefPubMed
8.
Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999;138:299-302.CrossRefPubMed
9.
Thunell M, Bjerle P, Stjernberg N. ECG abnormalities in patients with sarcoidosis. Acta Med Scand 1983;213:115-8.CrossRefPubMed
10.
Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest 1994;106:1021-4.CrossRefPubMed
11.
Brustow DJ, Tajik AJ, Bailey KR, DeRemee RA, Tailiercio CP. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 1989;63:478-82.CrossRef
12.
Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995;107:330-4.CrossRefPubMed
13.
Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med 2003;44:1030-6.PubMed
14.
Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.CrossRefPubMed
15.
Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002;105:1144-5.CrossRefPubMed
16.
Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.PubMed
17.
Ishimaru S, Tsujino I, Sakaue S, Oyama N, Takei T, Tsukamoto E, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:234-5.PubMed
18.
19.
Smedema JP, Snoep G, Van Kroonenburgh MP, Van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90.CrossRefPubMed
20.
Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001;110:520-7.CrossRefPubMed
21.
Vignaux O, Dhote R, Dudoc D, Blanche P, Devaux JY, Weber S, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr 2002;26:762-7.CrossRefPubMed
22.
Slater GM, Rodriguez ER, Lima JA, Bluemke DA. A unique presentation of cardiac sarcoidosis. AJR Am J Roentgenol 2003;180:1738-9.CrossRefPubMed
23.
24.
Serra JJ, Monte GU, Mello ES, Coral GP, Avila LF, Parga JR, et al. Images in cardiovascular medicine. Cardiac sarcoidosis evaluated by delayed-enhancement magnetic resonance imaging. Circulation 2003;107:e188-9.PubMed
25.
Hiraga H, Iwai K, Hiroe M, Omori F, Sekiguchi M, Tachibana T, et al. Guidelines for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases (in Japanese). Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 23-4.
26.
Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand Suppl 1988;724:1-56.CrossRefPubMed
27.
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.CrossRefPubMed
28.
Glopler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990;31:1749-56.
29.
Bartlett ML, Bacharach SL, Voipio-Pulkki LM, Dilsizian V. Artifactual inhomogeneities in myocardial PET and SPECT scans in normal subjects. J Nucl Med 1995;36:188-95.PubMed
30.
31.
Tadamura E, Yamamuro M, Kubo S, Kanao S, Hosokawa R, Kimura T, et al. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy. Circulation 2006;113:e771-3.CrossRefPubMed
32.
Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J 2007;29:418-22.CrossRefPubMed
33.
Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002.CrossRefPubMed
34.
Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105:224-9.CrossRefPubMed
35.
Hunold P, Schlosser T, Vogt FM, Eqqebrecht H, Schmermund A, Bruder O, et al. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. AJR Am J Roentgenol 2005;184:1420-6.CrossRefPubMed
36.
Osman S, Danpure HJ. The use 0f 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labeling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B 1992;19:183-90.CrossRefPubMed
37.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.PubMed
38.
Tamaki N, Kawamoto M, Takahashi N, Yonekura Y, Magata Y, Nohara R, et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: comparison with stress thallium imaging. J Am Coll Cardiol 1993;22:1621-7.CrossRefPubMed
39.
Tellier P, Valeyre D, Nitenberg A, Foult JM, Bedig G, Battesti JP. Cardiac sarcoidosis: reversion of myocardial perfusion abnormalities by dipyridamole. Eur J Nucl Med 1985;11(6-7):201-4.CrossRefPubMed
40.
Mikami R, Sekiguchi M, Ryuzin Y, Kobayashi F, Hiraga Y, Shimada Y, et al. Changes in the peripheral vasculature of various organs in patients with sarcoidosis—possible role of microangiopathy. Heart Vessels 1986;2:129-39.CrossRefPubMed
41.
Schulz-Menger J, Gross M, Messroghli D, Uhlich F, Dietz R, Friedrich MG. Cardiovascular magnetic resonance of acute myocardial infarction at a very early stage. J Am Coll Cardiol 2003;42:513-8.CrossRefPubMed
Metadata
Title
Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis
Authors
Hiroshi Ohira
Ichizo Tsujino
Shinji Ishimaru
Noriko Oyama
Toshiki Takei
Eriko Tsukamoto
Masatake Miura
Shinji Sakaue
Nagara Tamaki
Masaharu Nishimura
Publication date
01-05-2008
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0650-8

Other articles of this Issue 5/2008

European Journal of Nuclear Medicine and Molecular Imaging 5/2008 Go to the issue

Original article

The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer

Original Article

Left ventricular function and visual phase analysis with equilibrium radionuclide angiography in patients with biventricular device

Editorial commentary

Should we use more PET-CT in clinical cardiology?

Erratum

Erratum to PET imaging with hypoxia tracers: a must in radiation therapy

Original article

The diagnostic value of 124I-PET in patients with differentiated thyroid cancer

Focus on

Advances in prostate cancer imaging techniques and strategies